RNS Number : 3886R IQ-AI Limited 28 February 2023   IQ-AI Announces Orphan Drug Designation Status FDA grants orphan status to Gallium Maltolate for treating GBM IQ-AI Limited, (LSE: IQAI) (OTCQB: IQAIF), is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium maltolate

RNS Number : 1496M IQ-AI Limited 10 January 2023   IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS   IQ-AI Limited (“IQAI”) (LSE: IQAI) (OTCQB: IQAIF) a developer and manufacturer of medical image processing platforms, has today released a letter to shareholders on behalf of Michael Schmainda, CEO of IQ-AI’s wholly-owned subsidiary Imaging Biometrics (the “Company”), covering several material recent

RNS Number : 4535I IQ-AI Limited 02 December 2022   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which

RNS Number : 2244B IQ-AI Limited 30 September 2022   IQ-AI LIMITED ISSUES LETTER TO SHAREHOLDERS   Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB: IQAIF: LSE: IQAI), summarises the Company’s achievements in 2022 to date, which includes: ·      Company focuses on deployment of IB Clinic™ ·      IB NIMBLE™ connects experts to help treat metastatic

RNS Number : 5398A IQ-AI Limited 26 September 2022   26 September 2022 IQ-AI Limited (“IQ-AI” or the “Company”)   Issue of Warrants to Employees IQAI Limited (the “Company” or “IQAI”), the parent company of Wisconsin-based Imaging Biometrics, LLC (IB), which is focused on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more

RNS Number : 1650W IQ-AI Limited 16 August 2022   16 August 2022 IQ-AI Limited (the “Company” or the “Group”) Half Yearly Report for the Period Ended 30 June 2022 Chief Executive’s Statement I am pleased to announce IQ-AI Limited’s unaudited financial results for the six months ended 30 June 2022. For further information, please

RNS Number : 8120U IQ-AI Limited 03 August 2022   TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which

RNS Number : 9294R IQ-AI Limited 11 July 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Imaging Biometrics Announces Channel Partnership   IQ-AI Limited (OTCQB: IQAIF) (LSE: IQAI), is pleased to announce that its medical imaging analysis software, IB Clinic®, is now available via the newly launched Bayer Calantic platform. This latest distribution partnership

RNS Number : 2442N IQ-AI Limited 30 May 2022   30 May 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Result of AGM   IQ-AI Limited announces that at the annual general meeting of the Company held earlier today, all resolutions were duly passed.   The Directors of the Company accept responsibility for the

RNS Number : 3069N IQ-AI Limited 31 May 2022   31 May 2022   IQ-AI Limited (“IQ-AI” or the “Company”)   Imaging Biometrics Submits FDA 510(k) Application for IB Zero G Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams Milwaukee – 31 May 2022:  Imaging Biometrics, LLC (IB), a